| Expression pattern: |
DN |
| Associated gene: |
RBP1 |
| Associated microRNA: |
miR-1296-3p |
| Biological function: |
sensitizes cells to osimertinib treatment by inducing apoptosis; reduces cell viability; decreases tumorsphere formation and migration; tumor-suppressive in NSCLC/LUAD osimertinib-resistant context |
| Molecular mechanism: |
ceRNA mechanism: circSPINT2 sponges hsa-miR-1296-3p to enhance RBP1 expression, contributing to osimertinib sensitivity and apoptosis |
| Biological pathway or process: |
apoptosis (promotes); ceRNA regulation (promotes); migration (inhibits); stemness (inhibits); proliferation (inhibits) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Sanger Sequencing; Back-Splice Junction PCR / divergent primers PCR; Droplet digital PCR; RNA Pull-Down; RNA-seq; Transfection; Colony Formation Assay; Transwell Assay; Flow Cytometry（Non-apoptosis/cycle）; Western Blot; FISH / smFISH; IHC (Immunohistochemistry); In Vivo Animal Model; H&E Staining; Bioinformatics Analysis |
| Clinical significance: |
The secreted circSPINT2 may serve as a monitoring biomarker for osimertinib resistance status in LUAD. |
| Description: |
circSPINT2 (hsa_circ_0050818) is down-regulated in osimertinib-resistant LUAD/NSCLC models. It acts as a tumor-suppressive circRNA that increases osimertinib sensitivity by promoting drug-induced apoptosis via a ceRNA mechanism (sponging hsa-miR-1296-3p to upregulate RBP1). Secreted circSPINT2 is proposed as a potential monitoring biomarker for osimertinib resistance. |
| Confidence score: |
0.8204 |